VRDN Stock Overview
A biotechnology company, discover and develops treatments for serious and rare diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Viridian Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.79 |
| 52 Week High | US$27.20 |
| 52 Week Low | US$11.40 |
| Beta | 1.11 |
| 11 Month Change | -19.45% |
| 3 Month Change | 29.01% |
| 1 Year Change | 26.21% |
| 33 Year Change | 2.12% |
| 5 Year Change | 84.01% |
| Change since IPO | -89.10% |
Recent News & Updates
Recent updates
We're Not Very Worried About Viridian Therapeutics' (NASDAQ:VRDN) Cash Burn Rate
Nov 14
Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?
Sep 11Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way
Sep 10Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year
Jun 12Is Viridian Therapeutics (NASDAQ:VRDN) Using Debt Sensibly?
May 28Despite Lacking Profits Viridian Therapeutics (NASDAQ:VRDN) Seems To Be On Top Of Its Debt
Sep 12Is There An Opportunity With Viridian Therapeutics, Inc.'s (NASDAQ:VRDN) 44% Undervaluation?
May 15Is Viridian Therapeutics (NASDAQ:VRDN) Weighed On By Its Debt Load?
Apr 18Does Viridian Therapeutics (NASDAQ:VRDN) Have A Healthy Balance Sheet?
Jan 08Viridian: Excellent Early Data, Strong Cash, Great Strategy, Large Market
Sep 09Viridian Therapeutics board compensation committee approves inducement grants
Sep 02An Intrinsic Calculation For Viridian Therapeutics, Inc. (NASDAQ:VRDN) Suggests It's 49% Undervalued
Aug 22Shareholder Returns
| VRDN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.0% | -6.5% | -1.0% |
| 1Y | 26.2% | 14.6% | 30.3% |
Return vs Industry: VRDN exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: VRDN underperformed the US Market which returned 30.4% over the past year.
Price Volatility
| VRDN volatility | |
|---|---|
| VRDN Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VRDN's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: VRDN's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 94 | Steve Mahoney | www.viridiantherapeutics.com |
Viridian Therapeutics, Inc., a biotechnology company, discover and develops treatments for serious and rare diseases. The company’s product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED. It also provides VRDN-006 a preclinical program for autoimmune disease.
Viridian Therapeutics, Inc. Fundamentals Summary
| VRDN fundamental statistics | |
|---|---|
| Market cap | US$1.60b |
| Earnings (TTM) | -US$257.08m |
| Revenue (TTM) | US$302.00k |
5,191x
P/S Ratio-6.1x
P/E RatioIs VRDN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VRDN income statement (TTM) | |
|---|---|
| Revenue | US$302.00k |
| Cost of Revenue | US$159.77m |
| Gross Profit | -US$159.46m |
| Other Expenses | US$97.62m |
| Earnings | -US$257.08m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.25 |
| Gross Margin | -52,802.32% |
| Net Profit Margin | -85,127.15% |
| Debt/Equity Ratio | 2.9% |
How did VRDN perform over the long term?
See historical performance and comparison